Randomized phase I/II study of 5-azacytidine in combination with cytosine arabinoside [cytarabine] in patients with relapsed/refractory acute myelogenous leukemia or high risk myelodysplastic syndrome - SPORE

Trial Profile

Randomized phase I/II study of 5-azacytidine in combination with cytosine arabinoside [cytarabine] in patients with relapsed/refractory acute myelogenous leukemia or high risk myelodysplastic syndrome - SPORE

Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Jul 2012

At a glance

  • Drugs Azacitidine; Cytarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SPORE
  • Most Recent Events

    • 31 Jul 2012 Additional lead trial centre added as reported by ClinicalTrials.gov record.
    • 30 Oct 2009 Actual patient number (36) added as reported by ClinicalTrials.gov.
    • 30 Oct 2009 Actual end date (1 Oct 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top